Press Releases

Date Title and Summary Additional Formats
Toggle Summary Assembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients in a Late-Breaker Session at the EASL Conference
Robust antiviral activity observed in HBV patients Generally safe and well tolerated Planning underway for Phase 2a studies beginning summer 2018 Company to host conference call on Thursday, April 12 th at 8am ET / 2pm CEST INDIANAPOLIS and SAN FRANCISCO , April 12, 2018 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary Assembly Biosciences to Host Conference Call on April 12 to Review ABI-H0731 Interim Phase 1b Data in HBV Patients Featured in Late-Breaker Poster at EASL
INDIANAPOLIS and SAN FRANCISCO , April 10, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders
View HTML
Toggle Summary Assembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer Microbiome
Industry Leader Brings More than 20 Years of Experience, Including Scientific Strategy, Therapeutics and Microbiome Expertise INDIANAPOLIS and SAN FRANCISCO , April 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of
View HTML
Toggle Summary Assembly Biosciences Announces ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at The International Liver Congress™ (EASL)
INDIANAPOLIS and SAN FRANCISCO , March 28, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders
View HTML
Toggle Summary Assembly Biosciences Announces Additions to Management Team and Board of Directors
Accomplished industry veterans further strengthen leadership team; Graham Cooper joins as CFO and COO and Helen S. Kim is appointed to Board of Directors INDIANAPOLIS , March 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a
View HTML
Toggle Summary Assembly Biosciences to Present at Cowen’s 38th Annual Healthcare Conference
INDIANAPOLIS , March 05, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences to Participate in Leerink Partners 7th Annual Global Healthcare Conference
INDIANAPOLIS , , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
INDIANAPOLIS , Feb. 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences to Present at the J.P. Morgan Healthcare Conference
INDIANAPOLIS , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences Appoints Sue Mahony, PhD to Board of Directors
INDIANAPOLIS , Dec. 18, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML